Chronic Lymphocytic Leukemia Treatment Market
Chronic Lymphocytic Leukemia Treatment Market:Chronic lymphocytic is a common type of leukemia of WBC in adults, it is also known as β –cell chronic lymphocytic leukemia. β-cells lymphocytes are a type of WBC, which are produced in the bone marrow and developed in lymph nodes. These cells produce antibodies which fight infection. In chronic lymphocytic leukemia, β-cells are produced in an uncontrolled fashion and segregate in blood and bone marrow and they crowd out healthy blood cells. Majorly, chronic lymphocytic leukemia occurs in adults, however, cases are seen in children too. Chronic lymphocytic leukemia is diagnosed by testing complete blood count, gene test, flow cytometry and bone marrow tests.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-lymphocytic-leukemia-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
Due to increase in the number of cases, the market for chronic lymphocytic leukemia is expected to grow globally. According to WHO, chronic lymphocytic leukemia is more noticeable in developed nations such as North America and Europe due to genetic factors. The global increase in the number of the leukemia patients has increased from 123,379 in 2010 to 282,683 new cases for 2020. Factors such as genetic blood disorders, excessive exposure to carcinogenic chemicals and increase in aging population are contributing to the growth of the chronic lymphocytic leukemia treatment market. In addition to the above factors rising awareness, new drug development and innovation in oncology department increased R & D, and increasing incidence of comorbidities can expedite the growth of the chronic lymphocytic leukemia market. However, high cost of the treatment, stringent regulatory policies can cause setback in the growth of the chronic lymphocytic leukemia.
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-lymphocytic-leukemia-treatment-market/#ulp-c654SbFYO64MsOhu
Chronic lymphocytic leukemia treatment market is categorized as-
1. Drug type
• Targeted Drugs
• Purine Analogues
• Alkylating Agents
• Corticosteroids
• Other Drugs
2. Cancer type
• B-cell Chronic Lymphocytic Leukemia
• T-cell Chronic Lymphocytic Leukemia
• Natural Killer Chronic Lymphocytic Leukemia
3. Route of administration,
• Parenteral
• Oral
• Others
4. End users
Hospital Pharmacies, retail pharmacies, and online Pharmacies
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-lymphocytic-leukemia-treatment-market/#ulp-14mlyhjMGhVjZqa3
And lastly, it is divided into 5 geographical regions- North America, Europe, Latin America, the Middle East & Africa and Asia-Pacific. According to the American Cancer Society, approximately 15,000 new cases that are surfacing every year in the US. Chronic lymphocytic leukemia is more prominent in developed nations such as North America and Europe due to their sedentary and unhealthy lifestyle and genetic factors. The Asia-Pacific market will show considerable growth with the rise in R & D in the drug developing industries, and improving healthcare infrastructure in India and China.
Some important companies in chronic lymphocytic leukemia market are Genzyme Corporation (US), Ono Pharmaceuticals Co. Ltd. (Japan), AbbVie Inc. (U.S.), Infinity Pharmaceuticals (U.S.), AstraZeneca (UK), GlaxoSmithKline Plc (UK). In 2016, USFDA approved the drug name Venetoclax for the treatment chronic lymphocytic leukemia by Roche with 17p chromosome deletion and in 2014 Genentech had launched the GA101/RG7159 for the chronic lymphocytic leukemia treatment.
With the global market still in the nascent stage, conventionally chemo drugs are still dominating the chronic lymphocytic leukemia market. For e.g. Rituximab, Imbruvica, and Idelalisib are chemotherapy drugs which are used alone or in combination for the treatment of chronic lymphocytic leukemia. Collaborative agreement and co-development are being accepted for the treatment of chronic lymphocytic leukemia. For e.g. GSK and Genmab A/S have entered into co-development and collaborative agreement for the drug Arzerra (Ofatumumab), is used extensively for the treatment of chronic lymphocytic leukemia.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-lymphocytic-leukemia-treatment-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com